Editor’s note: This is not an exhaustive list. Drugmakers are listed in alphabetical order.
- AbbVie waived license restrictions on an HIV drug that may treat COVID-19. The drugmaker also pushed back its takeover of Allergan to May due to disruptions caused by the COVID-19 pandemic.
- Bayer fired an employee who broke quarantine rules in Beijing, China.
- Eli Lilly capped insulin costs at $35 per month in an effort to help patients afford the drug during the COVID-19 pandemic.
- Gilead asked the FDA to take back orphan drug status for its experimental drug, remdesivir, which is being tested to treat COVID-19. It also boosted production of remdesivir and had 1.5 million doses as of April 4.
- Johnson & Johnson partnered with the U.S. government to develop a vaccine for COVID-19, with the government investing $1 billion.
- Mylan delayed its merger with Upjohn until the second half of this year because of unexpected delays caused by the coronavirus pandemic.
- Novartis said it plans to conduct a 440-person clinical trial to determine the effectiveness of hydroxychloroquine against COVID-19.
- Novo Nordisk offered a free 90-day supply of insulin to patients who were financially affected by the COVID-19 pandemic.
- Regeneron teamed up with Sanofi to launch clinical trials to see if a drug they co-developed can treat symptoms of COVID-19.
- Rising Pharmaceuticals, a New Jersey-based drugmaker, slashed the price of its chloroquine tablets, a drug that may treat COVID-19, by more than half.
- Pfizer identified a lead COVID-19 drug candidate that it hopes to start testing on humans in the summer.
- Sage Therapeutics, a Massachusetts-based drugmaker, cut 53 percent of its workforce in an effort to save money.
- Sanofi partnered with GlaxoSmithKline to create a COVID-19 vaccine with funding from HHS.
More articles on pharmacy:
CVS, UCLA Health unite to free hospital beds for COVID-19 patients
NIH teams up with 16 drugmakers to speed COVID-19 vaccine development
16 recent drug, device recalls
